Acalabrutinib

FDA approved for human use

Companion animals trial suggest that acalabrutinib is safe and exhibits activity in canine B-cell lymphoma patients and support the use of canine lymphoma as a relevant model for human non-Hodgkin lymphoma (NHL).

Hydroxychloroquine

Phase II human trial completed

Demonstration of target inhibition in companion animal trial. Studies in dogs were used as a proof of target and refined measure of drug exposure.

Ibrutinib

FDA approved for human use

Validation of biomarker test for use in human trials; dose modulation. Companion animals trial demonstrated efficacy and surrogate endpoint.

Ganetespib

Phase III human trials

Proof-of-target for IND application; defined PK/PD relationship. Determined toxicity, biomarkers, and biologic activity

NHS-IL12

Phase I human trials ongoing

PK, PD, efficacy and toxicity studies were conducted in companion animals naturally affected with malignant melanoma

Sulphonamide PAC-1 or SPAC-1

Human trials were not conducted

Decision was made to not move forward with human studies based on companion animals trials results.

https://www.ncbi.nlm.nih.gov/books/NBK338437/

​

PAC-1

Phase I human trials ongoing

Assessed single-agent activity and toxicity for development of tolerable dosing regimen.

KPT-335

Phase I human trials ongoing

Determined dosing regimen and supportive care protocols in companion animals. Identified adverse events, dose, and regimen.

LMP400, LMP776 and LMP744

Phase I human trials ongoing

Phase I study for lymphoma-bearing dogs to evaluate differential efficacy, pharmacodynamics, toxicology, and pharmacokinetics, supporting their further clinical development.

Masitinib

Phase III human trials ongoing

Studies in companion animals confirmed inhibition and tumor response. Important proof of concept study. Masitinib is EMA-approved for veterinary use.